Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder

JAMA Oncol. 2023 Jun 1;9(6):864-866. doi: 10.1001/jamaoncol.2023.0351.
No abstract available

Plain language summary

This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were diagnosed with major depression disorder to create a scalable, rapidly effective depression treatment.

MeSH terms

  • Depression
  • Depressive Disorder, Major* / drug therapy
  • Humans
  • Neoplasms* / complications
  • Neoplasms* / drug therapy
  • Patients
  • Psilocybin / therapeutic use


  • Psilocybin